IV Ketamine & Spravato® for Postpartum Depression
When Depression and Substance Use Overlap, We Treat Both
Understanding Postpartum Depression
Postpartum depression is a medical condition, not a personal failing. We offer evidence-based ketamine treatment options for new mothers when conventional approaches haven’t provided sufficient relief.
Postpartum depression (PPD) is classified as a major depressive episode with peripartum onset — meaning it can begin during pregnancy or within the first weeks or months after delivery. It affects approximately 1 in 7 new mothers and is far more significant than the “baby blues” that typically resolve within two weeks of delivery.
PPD symptoms include persistent sadness or emptiness, difficulty bonding with your baby, overwhelming fatigue, loss of interest in daily life, feelings of worthlessness or guilt, irritability, and in some cases, intrusive thoughts. The dramatic hormonal shifts following delivery — particularly the rapid drop in estrogen and progesterone — are believed to disrupt neurotransmitter systems and contribute to these symptoms. Yet the precise etiology involves biological, psychological, and social factors unique to each mother.
“Despite its widespread prevalence, many women affected by postpartum depression have not received a formal medical diagnosis — and the delayed onset of traditional antidepressants underscores the critical need for novel therapeutic options.”
— BMC Pregnancy and Childbirth, 2025
A central challenge with treating PPD using conventional antidepressants is their delayed onset — typically two to six weeks before meaningful effect — and concerns about medication compatibility with breastfeeding. For mothers who are severely symptomatic or who have not responded to prior treatment, faster-acting alternatives matter enormously.
What the Research Shows
The evidence for ketamine and esketamine in postpartum contexts has grown considerably in recent years, though important nuances apply.
A 2024 meta-analysis in BMC Pregnancy and Childbirth (covering 18 RCTs and 3 retrospective studies involving 4,389 women) found that ketamine and esketamine significantly reduced postpartum depression scores and incidence in the one-week and four-week periods following delivery, particularly in women who received treatment during cesarean section. Evidence certainty was rated moderate.
A prominent BMJ study (Wang et al., 2024) found that a single low-dose injection of esketamine administered just after childbirth was associated with a 75% lower risk of experiencing significant depressive symptoms at 6 weeks postpartum, in mothers who had mild prenatal depressive symptoms.
1 in 7
New mothers affected by postpartum depression
75%
Reduction in risk of significant postpartum depressive symptoms with esketamine at 6 weeks (BMJ, 2024)
Hours
Timeframe for initial antidepressant effect with IV ketamine, versus weeks with conventional agents
Researchers at the MGH Center for Women’s Mental Health note that while the evidence for ketamine/esketamine in PPD is encouraging, most studies to date examined administration at the time of delivery rather than as a treatment for established PPD. The rapid clearance of ketamine from the maternal bloodstream and very low transfer to breast milk (relative infant dose below 1%) are considered favorable properties for this population — though current Spravato labeling recommends against breastfeeding, and we discuss this individually with each patient.
Our Approach to Postpartum Care
We evaluate postpartum patients with particular attention to the full picture: symptom severity, timing of onset, prior treatment history, breastfeeding goals, infant care responsibilities, and support systems. We work collaboratively with OB-GYNs, midwives, and maternal mental health therapists.
Who we may be able to help
• New mothers with postpartum depression that hasn’t responded to antidepressants or therapy
• Those who need faster symptom relief than conventional medications provide
• Mothers with co-occurring postpartum anxiety or intrusive thoughts
• Women with a history of treatment-resistant depression who experience PPD
• Patients whose OB or midwife has recommended further evaluation for interventional treatment
Regarding breastfeeding: The Spravato® (esketamine) prescribing label currently recommends against breastfeeding during treatment. Pharmacokinetic data on IV ketamine suggest the relative infant dose is below the generally accepted 10% safety threshold, though data remain limited. We discuss all relevant considerations during your consultation so you can make an informed decision alongside your pediatrician.